Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MYC, there is more to it than cancer

  • Zacarías-Fluck, Mariano F.|||0000-0002-7171-4268
  • Soucek, Laura|||0000-0002-4750-7971
  • Whitfield, Jonathan R.|||0000-0002-4925-7283
MYC is a pleiotropic transcription factor involved in multiple cellular processes. While its mechanism of action and targets are not completely elucidated, it has a fundamental role in cellular proliferation, differentiation, metabolism, ribogenesis, and bone and vascular development. Over 4 decades of research and some 10,000 publications linking it to tumorigenesis (by searching PubMed for "MYC oncogene") have led to MYC becoming a most-wanted target for the treatment of cancer, where many of MYC's physiological functions become co-opted for tumour initiation and maintenance. In this context, an abundance of reviews describes strategies for potentially targeting MYC in the oncology field. However, its multiple roles in different aspects of cellular biology suggest that it may also play a role in many additional diseases, and other publications are indeed linking MYC to pathologies beyond cancer. Here, we review these physiological functions and the current literature linking MYC to non-oncological diseases. The intense efforts towards developing MYC inhibitors as a cancer therapy will potentially have huge implications for the treatment of other diseases. In addition, with a complementary approach, we discuss some diseases and conditions where MYC appears to play a protective role and hence its increased expression or activation could be therapeutic.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer

  • Giuntini, Fabio
  • González-Larreategui, Íñigo|||0000-0002-0959-8497
  • Herencia-Ropero, Andrea|||0009-0002-9448-1484
  • Casacuberta-Serra, Sílvia|||0000-0002-2595-1115
  • Zacarías-Fluck, Mariano F.|||0000-0002-7171-4268
  • Arnal, Magdalena|||0000-0001-8647-9232
  • Pedretti, Flaminia
  • Martínez-Martín, Sandra|||0000-0003-4443-0697
  • Thabussot, Hugo
  • Cano, Virginia Castillo
  • Grueso, Judit|||0000-0003-1093-7940
  • Foradada Felip, Laia|||0000-0002-0589-4360
  • Serrano, Erika
  • López-Estévez, Sergio|||0000-0001-5355-8073
  • Rodriguez, Olga
  • Guzmán, Marta|||0000-0002-0924-9887
  • Rodriguez-Hernandez, Adela
  • Brasó-Maristany, Fara|||0000-0001-5440-9643
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Nonell, Lara|||0000-0002-8538-8213
  • Prat, Aleix|||0000-0003-2377-540X
  • Serra, Violeta|||0000-0001-6620-1065
  • Beaulieu, Marie-Eve|||0000-0001-5224-8436
  • Whitfield, Jonathan R.|||0000-0002-4925-7283
  • Massó Vallés, Daniel|||0000-0003-4231-0456
  • Soucek, Laura|||0000-0002-4750-7971
MYC is dysregulated in most human cancers and is a DNA damage response (DDR) modulator capable of both promoting genomic instability and enhancing DNA repair. Here, we show that Omomyc, the only direct MYC inhibitor that has completed a phase 1 trial, shuts down DDR genes in triple-negative breast cancer (TNBC), causing DDR defects and inducing DNA damage. Since DDR-deficient tumors are currently targeted by poly ADP-ribose polymerase inhibitors (PARPis), we tested combinations with Omomyc. We show that Omomyc-induced DNA damage is enhanced by PARPis and that the inhibitors cooperate even in models with intrinsic or acquired PARPi resistance, both in vitro and in vivo. Moreover, using patient-derived models and clinical samples, we reveal a role for MYC as a predictor of PARPi resistance. Overall, our research highlights the opportunity of combining MYC inhibition by Omomyc with PARPis in PARPi-resistant TNBC, where MYC transcriptional activity represents a predictive biomarker of resistance to therapy.